Literature DB >> 2867573

Buspirone: an anxiolytic without sedative effect.

W F Seidel, S A Cohen, N G Bliwise, W C Dement.   

Abstract

Twelve volunteers with a complaint of chronic insomnia participated in a placebo-controlled, double-blind, crossover study of the effects of buspirone t.i.d. on sleep pattern and daytime function. The drug was tested alone and in combination with flurazepam or triazolam. Buspirone alone did not impair objective measures of daytime wakefulness or performance. Impaired alertness was seen the day after bedtime administration of flurazepam but not after triazolam; buspirone did not alter these effects. Buspirone did not affect the Multiple Sleep Latency Test, a sensitive measure of changes in daytime alertness.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2867573     DOI: 10.1007/bf00432724

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  13 in total

1.  Proposed supplements and amendments to 'A Manual of Standardized Terminology, Techniques and Scoring System for Sleep Stages of Human Subjects', the Rechtschaffen & Kales (1968) standard.

Authors:  T Hori; Y Sugita; E Koga; S Shirakawa; K Inoue; S Uchida; H Kuwahara; M Kousaka; T Kobayashi; Y Tsuji; M Terashima; K Fukuda; N Fukuda
Journal:  Psychiatry Clin Neurosci       Date:  2001-06       Impact factor: 5.188

2.  Daytime alertness, insomnia, and benzodiazepines.

Authors:  W Dement; W Seidel; M Carskadon
Journal:  Sleep       Date:  1982       Impact factor: 5.849

3.  Role of drugs in traffic accidents.

Authors:  R Honkanen; L Ertama; M Linnoila; A Alha; I Lukkari; M Karlsson; O Kiviluoto; M Puro
Journal:  Br Med J       Date:  1980-11-15

4.  Acute effects of buspirone and alcohol on psychomotor skills.

Authors:  M J Mattila; K Aranko; T Seppala
Journal:  J Clin Psychiatry       Date:  1982-12       Impact factor: 4.384

5.  A double-blind comparison of buspirone and diazepam in outpatients with generalized anxiety disorder.

Authors:  J P Feighner; C H Merideth; G A Hendrickson
Journal:  J Clin Psychiatry       Date:  1982-12       Impact factor: 4.384

6.  Assessment of the abuse liability of buspirone in recreational sedative users.

Authors:  J O Cole; M H Orzack; B Beake; M Bird; Y Bar-Tal
Journal:  J Clin Psychiatry       Date:  1982-12       Impact factor: 4.384

7.  Psychological effects of buspirone.

Authors:  M Lader
Journal:  J Clin Psychiatry       Date:  1982-12       Impact factor: 4.384

Review 8.  Preclinical pharmacology of buspirone hydrochloride.

Authors:  P Skolnick; S M Paul; B A Weissman
Journal:  Pharmacotherapy       Date:  1984 Nov-Dec       Impact factor: 4.705

Review 9.  Buspirone hydrochloride: a unique new anxiolytic agent. Pharmacokinetics, clinical pharmacology, abuse potential and clinical efficacy.

Authors:  H L Goldberg
Journal:  Pharmacotherapy       Date:  1984 Nov-Dec       Impact factor: 4.705

10.  Comparison of buspirone in two separate studies.

Authors:  H L Goldberg; R Finnerty
Journal:  J Clin Psychiatry       Date:  1982-12       Impact factor: 4.384

View more
  8 in total

1.  Pharmacodynamic effects of buspirone and clobazam.

Authors:  C Alford; J Z Bhatti; S Curran; G McKay; I Hindmarch
Journal:  Br J Clin Pharmacol       Date:  1991-07       Impact factor: 4.335

Review 2.  Drug treatment of patients with insomnia and excessive daytime sleepiness: pharmacokinetic considerations.

Authors:  S Nishino; E Mignot
Journal:  Clin Pharmacokinet       Date:  1999-10       Impact factor: 6.447

3.  A metabolite of buspirone increases locus coeruleus activity via alpha 2-receptor blockade.

Authors:  G Engberg
Journal:  J Neural Transm       Date:  1989       Impact factor: 3.575

4.  Inhibition of REM sleep by ipsapirone, a 5HT1A agonist, in normal volunteers.

Authors:  J C Gillin; W Jernajczyk; D C Valladares-Neto; S Golshan; M Lardon; S M Stahl
Journal:  Psychopharmacology (Berl)       Date:  1994-12       Impact factor: 4.530

5.  The influence of ipsapirone, a 5-HT1A agonist, on sleep patterns of healthy subjects.

Authors:  H S Driver; M J Flanigan; A J Bentley; H G Luus; C M Shapiro; D Mitchell
Journal:  Psychopharmacology (Berl)       Date:  1995-01       Impact factor: 4.530

Review 6.  Buspirone. A preliminary review of its pharmacological properties and therapeutic efficacy as an anxiolytic.

Authors:  K L Goa; A Ward
Journal:  Drugs       Date:  1986-08       Impact factor: 9.546

7.  Novel 1-(2-pyrimidin-2-yl)piperazine derivatives as selective monoamine oxidase (MAO)-A inhibitors.

Authors:  Betül Kaya; Leyla Yurttaş; Begüm Nurpelin Sağlik; Serkan Levent; Yusuf Özkay; Zafer Asim Kaplancikli
Journal:  J Enzyme Inhib Med Chem       Date:  2017-12       Impact factor: 5.051

8.  Behavioral Effects of Buspirone in Juvenile Zebrafish of Two Different Genetic Backgrounds.

Authors:  Amira Abozaid; Robert Gerlai
Journal:  Toxics       Date:  2022-01-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.